GlassScriptPhysician profile
Selena Wong
NPI 1164787628
$5,672.83
in general payments reported to CMS, 2019-2025
23 companies · $772 in 2025
The $772 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $423 · 2021: $817 · 2022: $555 · 2023: $779 · 2024: $1,025 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $804.29 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $586.92 | 2023-2025 | Acthar |
| Allergan, INC. | $480.30 | 2019-2021 | |
| Alcon Vision LLC | $455.54 | 2022-2025 | Rocklatan, Rhopressa, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $420.35 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $404.18 | 2023-2025 | Miebo, Xiidra |
| Ivantis, INC | $376.91 | 2021 | |
| Sight Sciences, INC. | $289.73 | 2022 | |
| Shire North American Group INC | $287.42 | 2019 | |
| Oyster Point Pharma, INC. | $267.06 | 2023-2025 | Tyrvaya |
| Amgen INC. | $194.72 | 2020-2025 | Tepezza |
| Astellas Pharma US INC | $146.57 | 2023 | |
| Carl Zeiss Meditec, INC. | $125.00 | 2019 | |
| Dompe US, INC. | $125.00 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $121.76 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $113.83 | 2019 | |
| Eyevance Pharmaceuticals LLC | $108.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.08 | 2020-2021 | |
| Coopervision INC. | $63.42 | 2024-2025 | Synergeyes Contact Lens |
| Thea Pharma INC. | $39.15 | 2022-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $28.73 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $24.83 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selena Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.